InsiderSignalSign in

← Insider buys

KOD

Kodiak Sciences Inc. · Healthcare

Insiders bought $217.0M of Kodiak Sciences Inc. in the last 12 months

1 insider bought on 2 days.

$217.0MBought, 12 mo

$4.9MSold, 12 mo

$5.5BMarket cap

KOD over the last year

Insider buy filed (2 days)

Largest buyers, last 12 months

BAKER BROS. ADVISORS LPDirector · 2 days$217.0M

KOD after insider buys

3 months after each buy, from the first price a copier could get.

−41.0%Average

−39.3 ptsVs S&P 500

1 of 7Higher

7 buys since 2018 with 3 months of prices.

Every filing

62 insider filings since 2018, newest first

John A. Borgeson · Chief Financial Officer

$2.7M−12.4%3d ago

BAKER BROS. ADVISORS LP · Director

$63.4M+3.7%Sep 30

BAKER BROS. ADVISORS LP · Director

$35.0M+2.2%Sep 30

BAKER BROS. ADVISORS LP · Director

$58.6M+4.4%Sep 30

John A. Borgeson · Chief Financial Officer

$1.0M−12.4%Jun 5

John A. Borgeson · CFO

$1.2M−14.0%Apr 2

Baker Bros. Advisors LP · Director and 10% owner

$60.0M+17.0%Dec 19

John A. Borgeson · Insider

$39K−2.0%Jun 16

Jason Ehrlich · Insider

$32K−5.0%Jun 16

John A. Borgeson · Insider

$31K−2.0%Jun 17

Baker Bros. Advisors LP · Director and 10% owner

$4.4M+4.0%Jun 6

Victor Perlroth · Chair, CEO and 10% owner

$12.3M−38.0%Feb 28

Baker Bros. Advisors LP · Director and 10% owner

$21.8M+3.0%Feb 17

Baker Bros. Advisors LP · Director and 10% owner

$18.1M+2.0%Jan 31

Baker Bros. Advisors LP · Director and 10% owner

$28.8M+3.0%Jan 25

Jason Ehrlich · Insider

$447K−12.0%Jan 24

Jason Ehrlich · Insider

$609K−12.0%Dec 22

Jason Ehrlich · Insider

$689K−12.0%Nov 24

John A. Borgeson · Insider

$101K−1.0%Nov 12

Jason Ehrlich · Insider

$777K−12.0%Oct 22

Baker Bros. Advisors LP · Director and 10% owner

$8.3M+1.0%Oct 1

Jason Ehrlich · Insider

$694K−12.0%Sep 22

Baker Bros. Advisors LP · Director and 10% owner

Baker Bros. Advisors LP · Director and 10% owner

Jason Ehrlich · Insider

$636K−12.0%Aug 24

Baker Bros. Advisors LP · Director and 10% owner

$10.0M+1.0%Aug 19

Baker Bros. Advisors LP · Director and 10% owner

$9.0M+1.0%Aug 13

Jason Ehrlich · Insider

$600K−12.0%Jul 22

Jason Ehrlich · Insider

$590K−10.0%Jun 23

John A. Borgeson · Insider

$104K−1.0%Jun 17

Jason Ehrlich · Insider

$118K−2.0%Jun 17

Jason Ehrlich · Insider

$564K−10.0%May 24

Jason Ehrlich · Insider

$773K−10.0%Apr 22

Jason Ehrlich · Insider

$914K−10.0%Mar 24

John A. Borgeson · Insider

$650K−3.0%Mar 12

Jason Ehrlich · Insider

$874K−12.0%Feb 24

Jason Ehrlich · Insider

$4.4M−35.0%Jan 22

Jason Ehrlich · Insider

$1.0M−12.0%Dec 23

Jason Ehrlich · Insider

$965K−14.0%Nov 24

Jason Ehrlich · Insider

$750K−15.0%Oct 29

Jason Ehrlich · Insider

$647K−15.0%Oct 27

Jason Ehrlich · Insider

$545K−14.0%Oct 22

Jason Ehrlich · Insider

$375K−10.0%Oct 15

Jason Ehrlich · Insider

$157K−5.0%Oct 13

Jason Ehrlich · Insider

$364K−17.0%Sep 23

Baker Bros. Advisors LP · Director and 10% owner

$15.3M+3.0%Sep 8

Jason Ehrlich · Insider

$327K−17.0%Aug 24

Baker Bros. Advisors LP · Director and 10% owner

$9.8M+2.0%Aug 21

Jason Ehrlich · Insider

$351K−17.0%Jul 22

Jason Ehrlich · Insider

$421K−18.0%Jun 24

About Kodiak Sciences Inc.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.